GA-10 (Clone 4) is a subclone of the GA-10 (ATCC CRL-2392)
cell line derived by culturing the parental line on a feeder layer.
GA-10 was derived in 1996 from lymphoma cells circulating in the peripheral blood of a patient with a clinically aggressive, chemo-refractory Burkitt's Lymphoma.
The patient had been treated unsuccessfully with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP chemotherapy).
This clone of cells also appears to express high levels of CD77 (approximately 90%); CD77 is also known as Burkitt's lymphoma antigen (BLA).
GA-10 (Clone-4) cells exhibit sensitivity to Shiga Toxin (Stx) in toxicity studies.